Your search returned the following 35 documents:

35. HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge
    Martin Obermeier, Alejandro Pironti, Thomas Berg, Patrick Braun, Martin Däumer, Josef Eberle, Robert Ehret, Rolf Kaiser, Niels Kleinkauf, Klaus Korn, Claudia Kücherer, Harm Müller, Christian Noah, Martin Stürmer, Alexander Thielen, Eva Wolf, and Hauke Walter
    Intervirology 55: 102-107, 2012
    
34. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis
    Martin Däumer, Rolf Kaiser, Rolf Klein, Thomas Lengauer, Bernhard Thiele, and Alexander Thielen
    BMC Medical Informatics and Decision Making 11 (1): 30,1-30,8, 2011
    
33. In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing
    Stefanie Knoepfel, Francesca Di Giallonardoc, Martin Däumer, Alexander Thielen, and Karin J Metzner
    Journal of Virological Methods 71 (2): 329-338, 2011
    
32. Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach
    Saleta Sierra, Rolf Kaiser, Nadine Lübke, Alexander Thielen, Eugen Schuelter, Eva Heger, Martin Däumer, Stefan Reuter, Stefan Esser, Gerd Fätkenheuer, Herbert Pfister, Mark Oette, and Thomas Lengauer
    Journal of Visualized Experiments 58: e3264,1-e3264,9, 2011
    
31. Short Communication: Selection of Thymidine Analogue Resitance Mutational Patterns in Children from a Common HIV Type 1 Subtype G Source
    Martin Däumer, Sabine Awerkiew, Saleto Sierra Aragon, Vladimir Kartashev, Tatjana Poplavskaja, Rolf Klein, Nadine Sichtig, Bernhard Thielen, Thomas Lengauer, Kirsten Roomp, Herbert Pfister, and Rolf Kaiser
    AIDS Research and Human Retroviruses 26 (3): 275-278, 2010
    
30. Evolution of raltegravir resistance during therapy
    Nadine Sichtig, Saleta Sierra, Rolf Kaiser, Martin Däumer, Stefan Reuter, Eugen Schülter, André Altmann, Gerd Fätkenheuer, Ulf Dittmer, Herbert Pfister, and Stefan Esser
    Journal of antimicrobial chemotherapy 64 (1): 25-32, 2009
    
29. Performance of genotypic coreceptor measurement using geno2pheno[coreceptor] in B- and non-B HIV subtypes in a large cohort of therapy-experienced patients in Germany
    Alexander Thielen, Nadine Sichtig, Patrick Braun, Martin Däumer, Hauke Walter, Christian Noah, Eva Wolf, Harm Müller, Martin Stürmer, Thomas Lengauer, Rolf Kaiser, and Martin Obermeier
    In: Reviews in Antiviral Therapy, Stockholm, Sweden, 2009, 99-99
    
28. Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database
    André Altmann, Martin Däumer, Niko Beerenwinkel, Yardena Peres, Eugen Schülter, Joachim Büch, Soo-Yon Rhee, Anders Sönnerborg, W. Jeffrey Fessel, Robert W. Shafer, Maurizio Zazzi, Rolf Kaiser, and Thomas Lengauer
    The Journal of Infectious Diseases 199 (7): 999-1006, 2009
    
27. Determination of HIV-1 co-receptor usage in German patients – comparison of genotypic methods with the TROFILE® phenotypic assay
    Martin Obermeier, Thomas Berg, Nadine Sichtig, Patrick Braun, Martin Däumer, Hauke Walter, Christian Noah, Eva Wolf, Harm Müller, Martin Stürmer, Alexander Thielen, and Rolf Kaiser
    In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008, 123 p.
    
26. Determination of HIV-1 coreceptor usage in German patients - comparison of genotypic methods with the TROFILE phenotypic assay
    Martin Obermeier, Nadine Sichtig, Patrick Braun, Martin Däumer, Hauke Walter, Christian Noah, Eva Wolf, Harm Müller, Martin Stürmer, Rolf Kaiser, and Alexander Thielen
    In: Antiviral Therapy, Sitges, Spain, 2008, A112 p.
    
25. Inferring viral tropism from genotype with massively parallel sequencing; qualitative and quantitative analysis
    Martin Däumer, Rolf Kaiser, Rolf Klein, Thomas Lengauer, Bernhard Thiele, and Alexander Thielen
    In: Antiviral Therapy, Sitges, Spain, 2008, A101 p.
    
24. Fifteen years of env C2V3C3 evolution in six individuals clonally infected with human immunodeficiency virus type 1
    Bernd Kupfer, Tobias Sing, Peter Schüffler, Rabea Hall, Ralf Kurz, Astrid McKeown, Karl-Eduard Schneweis, Wolfgang Eberl, Johannes Oldenburg, Hans H. Brackmann, Jürgen K. Rockstroh, Ulrich Spengler, Martin Däumer, Rolf Kaiser, Thomas Lengauer, and Bertfried Matz
    Journal of Medical Virology 79 (11): 1629-1639, 2007
    
23. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance
    Andre Altmann, Niko Beerenwinkel, Tobias Sing, Igor Savenkov, Martin Däumer, Rolf Kaiser, Soo-Yon Rhee, W Jeffrey Fessel, Robert W Shafer, and Thomas Lengauer
    Antiviral Therapy 12 (2): 169-178, 2007
    
22. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates
    Tobias Sing, Andrew J. Low, Niko Beerenwinkel, Oliver Sander, Peter K. Cheung, Francisco S. Domingues, Joachim Büch, Martin Däumer, Rolf Kaiser, Thomas Lengauer, and P. Richard Harrigan
    Antiviral Therapy 12 (7): 1097-1106, 2007
    
21. Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level
    G. Ahlenstiel, Kirsten Roomp, Martin Däumer, T. Nattermann, M. Vogel, J.K. Rockstroh, Niko Beerenwinkel, R. Kaiser, H.-D. Nischalke, T. Sauerbruch, Thomas Lengauer, and U. Spengler
    Clinical and Vaccine Immunology 14 (10): 1266-1273, 2007
    
    
20. Validation of geno2pheno and THEO on a large independent clinical dataset
    Andre Altmann, Martin Däumer, Tobias Sing, Niko Beerenwinkel, Hauke Walter, Rolf Kaiser, and Thomas Lengauer
    In: Proceedings of the 5th European HIV Drug Resistance Workshop, Cascais, Portugal, 2007
    
19. Arevir: A Secure Platform for Designing Personalized Antiretroviral Therapies Against HIV
    Kirsten Roomp, Niko Beerenwinkel, Tobias Sing, Eugen Schülter, Joachim Büch, Saleta Sierra-Aragon, Martin Däumer, Daniel Hoffmann, Rolf Kaiser, Thomas Lengauer, and Joachim Selbig
    Lecture Notes in Computer Science 4075: 185-194, 2006
    
18. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients
    Jens Verheyen, Elena Litau, Tobias Sing, Martin Däumer, Melanie Balduin, Mark Oette, Gerd Fätkenheuer, Jürgen K. Rockstroh, Ulrike Schuldenzucker, Daniel Hoffmann, Herbert Pfister, and Rolf Kaiser
    Antiviral Therapy 11 (7): 879-887, 2006
    
17. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART
    Clara Lehmann, Martin Däumer, Ibrahim Bousaad, Tobias Sing, Niko Beerenwinkel, Thomas Lengauer, Norbert Schmeisser, Christoph Wyen, Gerd Fätkenheuer, and Rolf Kaiser
    Journal of Clinical Virology 37 (4): 300-304, 2006
    
16. Characterization of novel HIV Drug Resistance Mutations using clustering, multidimensional scaling and SVM-based feature ranking
    Tobias Sing, Valentina Svicher, Niko Beerenwinkel, Francesca Ceccherini-Silberstein, Martin Däumer, Rolf Kaiser, Hauke Walter, Klaus Korn, Daniel Hoffmann, Mark Oette, Jürgen K. Rockstroh, Gerd Fätkenheuer, Carlo-Federico Perno, and Thomas Lengauer
    In: Knowledge Discovery in Databases: PKDD 2005., Porto, Portugal, 2005, 285-296
    
15. Computational methods for the design of effective therapies against drug resistant HIV strains
    Niko Beerenwinkel, Tobias Sing, Thomas Lengauer, Jörg Rahnenführer, Kirsten Roomp, Igor Savenkov, Roman Fischer, Daniel Hoffmann, Joachim Selbig, Klaus Korn, Hauke Walter, Thomas Berg, Patrick Braun, Gerd Fätkenheuer, Mark Oette, Jürgen Rockstroh, Bernd Kupfer, Rolf Kaiser, and Martin Däumer
    Bioinformatics 21 (21): 3943-3950, 2005
    
14. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance
    Niko Beerenwinkel, Martin Däumer, Tobias Sing, Jörg Rahnenführer, Thomas Lengauer, Joachim Selbig, Daniel Hoffmann, and Rolf Kaiser
    The Journal of Infectious Diseases 191 (11): 1953-1960, 2005
    
13. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy
    Melanie Balduin, Niko Beerenwinkel, Saleta Sierra, Martin Däumer, Jürgen Rockstroh, Mark Oette, Gerd Fätkenheuer, Bernd Kupfer, Daniel Hoffmann, Joachim Selbig, Herbert Pfister, and Rolf Kaiser
    J Clin Virol 34 (4): 277-287, 2005
    
12. Geno2pheno[coreceptor]: a tool for predicting coreceptor usage from genotype and for monitoring coreceptor-associated sequence alterations
    Tobias Sing, Niko Beerenwinkel, Rolf Kaiser, Daniel Hoffmann, Martin Däumer, and Thomas Lengauer
    In: Proceedings of the 3rd European HIV Drug Resistance Workshop, Athens, Greece, 2005
    
11. Learning multiple evolutionary pathways from cross-sectional data
    Niko Beerenwinkel, Jörg Rahnenführer, Martin Däumer, Daniel Hoffmann, Rolf Kaiser, Joachim Selbig, and Thomas Lengauer
    Journal of Computational Biology 12 (6): 584-598, 2005
    
10. Stable coreceptor usage of HIV-1 in patients with ongoing treatment failure on HAART
    Rolf Kaiser, Ibo Boussaad, C. Lehmann, Martin Däumer, Tobias Sing, N. Schmeisser, C. Wyen, and Gerd Fätkenheuer
    In: Proceedings of the 3rd European HIV Drug Resistance Workshop, Athens, Greece, 2005
    
9. Computing the genetic barrier
   Niko Beerenwinkel, Tobias Sing, Martin Däumer, Rolf Kaiser, and Thomas Lengauer
   In: XII International HIV Drug resistance Workshop, Tenerife, Spain, 2004, S125-S125
   
8. Learning multiple evolutionary pathways from cross-sectional data
   Niko Beerenwinkel, Jörg Rahnenführer, Martin Däumer, Daniel Hoffmann, Rolf Kaiser, Joachim Selbig, and Thomas Lengauer
   In: RECOMB 2004 : proceedings of the Eighth Annual International Conference on Research in Computational Molecular Biology, San Diego, USA, March, 27-31, 2004, 36-44
   
7. Bioinformatikmethoden für die Optimierung antiviraler Kombinationstherapien
   Niko Beerenwinkel, Martin Däumer, Daniel Hoffmann, Rolf Kaiser, Joachim Selbig, and Thomas Lengauer
   In: MPG Jahrbuch, 2003, 481-486
   
6. Estimating effective drug combinations against drug-resistant mutants from genotypes
   Niko Beerenwinkel, Martin Däumer, Rolf Kaiser, Hauke Walter, Klaus Korn, Daniel Hoffmann, Joachim Selbig, and Thomas Lengauer
   In: Proceedings of the 1st European HIV Drug Resistamce Workshop, Luxembourg, March 6-8, 2003, 2003, 18-18
   
5. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes
   Niko Beerenwinkel, Martin Däumer, Mark Oette, Klaus Korn, Daniel Hoffmann, Rolf Kaiser, Thomas Lengauer, Joachim Selbig, and Hauke Walter
   Nucleic Acids Research 31 (13): 3850-3855, 2003
   
4. Methods for optimizing antiviral combination therapies
   Niko Beerenwinkel, Thomas Lengauer, Martin Däumer, Rolf Kaiser, Hauke Walter, Klaus Korn, Daniel Hoffmann, and Joachim Selbig
   Bioinformatics 19 (Supplement): i16-i25, 2003
   
3. Tree models for the evolution of drug resistance
   Niko Beerenwinkel, Rolf Kaiser, Jörg Rahnenführer, Martin Däumer, Daniel Hoffmann, Joachim Selbig, and Thomas Lengauer
   In: XII International HIV Drug resistance Workshop, Los Cabos, Mexico, June 10 - June 14, 2003, S107-S107
   
2. Neue Wege zur Optimierung von Anti-HIV Therapien
   Niko Beerenwinkel, Martin Däumer, Daniel Hoffmann, Rolf Kaiser, Klaus Korn, Thomas Lengauer, Barbara Schmidt, Hauke Walter, and Joachim Selbig
   BIOforum 24 (12): 912-914, 2001
   
1. Geno2pheno is predictive of short-term virological response
   Niko Beerenwinkel, Thomas Lengauer, Martin Däumer, S. Sierra, Barbara Schmidt, Hauke Walter, Klaus Korn, Mark Oette, Gerd Fätkenheuer, J. Rockstroh, Daniel Hoffmann, Rolf Kaiser, and Joachim Selbig
   In: Proceedings from the 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scotsdale, Arizona, 2002, 74-74, paper no. 89.